ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January
ScripWho: Grünenthal/Valinor Pharma What: Grünenthal is buying privately held US biotech Valinor on the strength of its lone commercial product, Movantik. Why: Grünenthal is acquiring Valinor to gain
ScripThe recent partial success of Vertex Pharmaceuticals Incorporated ’s non-opioid product VX-548 in a pair of acute pain studies positions the product as potentially the first new non-opioid analgesic
Pink SheetUS FDA’s flagship expedited review programs – the breakthrough therapy designation and its younger cousin, the biologics-focused regenerative medicine advanced therapy designation – have added new des